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ABSTRACT Background: Antimicrobial prophylaxis is commonly administered to patients undergoing left
ventricular assist device (LVAD) surgeries to prevent infectious complications. However, optimal surgi-
cal infection prophylaxis (SIP) for LVAD surgeries is not well defined. Methods: We conducted an elec-
tronic survey to characterize LVAD SIP used at different centers performing LVAD implantation. Results:
Responses were received from 23 of 85 centers (27%). Of 21 centers that provided usable data
about their LVAD SIP regimens for nonpenicillin allergic patients, 42.9% reported using a four-drug reg-
imen (three antibiotics plus fluconazole), 23.8% reported using a three-drug regimen (three antibiotics or
two antibiotics plus fluconazole), 23.8% reported using a regimen of two antibiotics, and 9.5% reported us-
ing vancomycin alone. A similar pattern was observed among SIP regimens for penicillin-allergic patients.
Criteria for discontinuation of SIP and use of decolonization strategies also varied widely across centers.
Conclusions: Our results demonstrate wide variability in LVAD SIP regimens and underscore the lack of
consensus regarding best practice. doi: 10.1111/j.1540-8191.2011.01262.x (J Card Surg 2011;26:440-443)
INTRODUCTION
Left ventricular assist device (LVAD) use continues
to burgeon both as a bridge to heart transplantation as
well as longer term “destination therapy.”1 Infection
remains the most serious complication of LVAD sup-
port and a leading cause of mortality, morbidity, and
decreased quality of life.2 Data from the 2006 to 2009
interagency registry for mechanical circulatory support
(INTERMACS) identified infection as the cause of 16%
of deaths post-LVAD implantation, second only to heart
failure. Previous reports have described infection rates
between 13% and 80% among LVAD recipients.3
Prevention of LVAD infection using appropriate sur-
gical infection prophylaxis (SIP) is especially critical
among patients undergoing implantation for destina-
tion therapy since successful treatment of a serious
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device infection generally requires prompt removal fol-
lowed by transplantation.3 Despite well-founded con-
cerns for device-associated infection, an optimal SIP
regimen is not well defined. Although current guide-
lines recommend limiting the duration of prophylaxis
to no longer than 48 hours after cardiac surgery, these
general guidelines are difficult to apply to LVAD implan-
tation.4 Patients undergoing LVAD placement are clin-
ically distinct from individuals undergoing scheduled
cardiac procedures such as valve replacement or coro-
nary artery bypass grafting. In particular, patients who
require LVAD support are usually critically ill often with
multiple indwelling lines and catheters. Many spend
an extended period of time in an intensive care unit
(ICU) prior to surgery and a large portion require de-
layed sternal closure and transfusion of blood products.
These and other factors increase the risk of infection
well above the rates associated with general cardiac
surgeries.3
Despite considerable risk, there is a lack of consen-
sus on the best approach to SIP for LVADs; practices
can vary greatly from center to center. The prolonged
use of antimicrobial agents is not therapeutically neu-
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antimicrobials are at increased risk of Clostridium dif-
ficile infection as well as subsequent infection with
antimicrobial-resistant organisms.5 Such acquisition of
antimicrobial resistance not only impacts the patients
receiving treatment, but also represents a broader chal-
lenge for infection control and antimicrobial steward-
ship programs. At our institution, the duration and
choice of agents used for SIP has evolved since the
first LVAD was implanted in 1996. In particular, the
duration of vancomycin prophylaxis has decreased
significantly.6
With increasing numbers of devices being placed,
LVAD SIP practices deserve closer attention. Given
these concerns, we conducted a brief survey to
evaluate SIP practices at different centers performing
LVAD implantation.
TABLE 1
Reported Surgical Infection Prophylaxis Regimens for Left Ventricular Assist Device Placement
Number of Respondents










Vancomycin Pip/Tazo Fluconazole 1
Vancomycin Rifampin Quinolone 1
Vancomycin Fluconazole Ciprofloxacin 1
Vancomycin Fluconazole Cefepime 1
TMP/SMX Rifampin Fluconazole 1
Four-drug Regimen
Vancomycin Rifampin Fluconazole Cefazolin 2
Vancomycin Quinolone Fluconazole Cefepime 1
Vancomycin Rifampin Fluconazole Cefepime 1
Vancomycin Rifampin Fluconazole Quinolone 1
Vancomycin Rifampin Quinolone Fluconazole 3
Vancomycin Rifampin Pip/Tazo Fluconazole 1







TMP/SMX Rifampin Fluconazole 1
Vancomycin Quinolone Fluconazole 2
Vancomycin Levofloxacin Aztreonam 1
Vancomycin Fluconazole Aztreonam 1
Vancomycin Rifampin Levofloxacin 1
Four-drug Regimen
Vancomycin Quinolone Fluconazole Cefepime‡ 1
Vancomycin Rifampin Fluconazole ID consult for cefepime substitution 1
Vancomycin Rifampin Quinolone Fluconazole 6
∗Number of respondents providing data = 21.
†Number of respondents providing data = 20.
‡Unable to clarify with respondent.
Pip/Tazo = piperacillin/tazobactam, TMP/SMX = trimethoprim/sulfamethoxazole.
METHODS
Centers for Medicaid and Medicare Services
approved heart transplant centers were contacted
to identify a clinical pharmacist who could com-
plete a questionnaire about LVAD SIP regimens
(http://www.cms.gov/CertificationandComplianc/20_
Transplant.asp). In October 2009, the questionnaire
was sent electronically to these pharmacists. The
survey recorded basic information about the center’s
LVAD program (annual volume, date of inception, etc.)
along with characteristics of the preferred SIP regi-
mens. Descriptive statistics were used to characterize
responses. This study was approved by University
of Michigan Medical School’s Institutional Review
Board.
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We received responses to the electronic survey from
23 of 85 transplant centers (27%). Most responding
centers were either university hospitals (56.5%) or
hospitals closely affiliated with an academic institution
(30.4%). Nine institutions (39.1%) had been implant-
ing LVADs for >10 years; six (26.1%) had <5 years
of experience. In terms of operative volume in 2008,
six (26.1%) centers implanted >20 LVADs in 2008; an-
other six reported 10 to 20 devices for 2008. All but two
centers reported a formal SIP policy for LVAD place-
ment (although both centers reported that they were
actively developing a policy).
SIP regimens varied widely across institutions
(Table 1). Twenty-one institutions provided usable
data about their LVAD SIP regimens for nonpenicillin-
allergic patients. Nine institutions (42.9%) reported us-
ing a four-drug regimen consisting of three antibiotics
plus fluconazole. Most commonly, these regimens in-
cluded vancomycin, a cephalosporin or quinolone, and
rifampin. Five institutions (23.8%) reported using a
three-drug regimen consisting of three antibiotics or
two antibiotics plus fluconazole. Another five institu-
tions (23.8%) reported a two-drug antibiotic regimen
and two institutions (9.5%) used vancomycin alone.
Similar patterns were observed among the 20 insti-
tutions providing usable data for penicillin-allergic pa-
tients; four-drug, three-drug, two-drug, and single-drug
antimicrobial regimens were used among 40%, 30%,
15%, and 15% of institutions, respectively.
Thirteen centers (61.9%) reported using some type
of decolonization strategy prior to surgery. Specific ap-
proaches included mupirocin to the nares (12 of 13)
and/or chlorhexidine washes (6 of 13), with five cen-
ters using both mupirocin and chlorhexidine.
Criteria for discontinuation of SIP also varied. Of
the 20 institutions providing data, nine (45%) reported
discontinuing antimicrobials at 48 hours postopera-
tively; one center discontinued therapy at 24 hours
postoperatively, another at 72 hours. Other criteria in-
cluded: after six doses; at the attending physician’s
discretion; after sternal closure; when chest tubes
are removed; automatically stopped, but criteria not
specified.
DISCUSSION
The above results suggest wide variability in LVAD
SIP regimens among centers responding to our elec-
tronic survey. Several centers reported using the SIP
protocol outlined in the randomized evaluation of me-
chanical assistance therapy for congestive heart failure
(REMATCH) trial including vancomycin, levofloxacin,
rifampin, and fluconazole along with mupirocin.1 Crite-
ria for stopping SIP varied even more with less than half
of institutions routinely discontinuing SIP at 48 hours
postoperatively.
Despite the considerable morbidity and mortality as-
sociated with LVAD infection as well as ongoing ef-
forts to improve antimicrobial use, studies evaluating
antimicrobial prophylaxis among LVAD recipients are
lacking. Although this work is limited by the small sam-
ple size and the lack of site-specific infection rates from
the participating centers, the results of this survey do
demonstrate wide variability in SIP regimens across in-
stitutions underscoring the lack of consensus regarding
best practices.
As a larger portion of LVAD use is shifted toward
long-term or destination support, it is essential that the
relative risks and benefits of different SIP approaches
are critically evaluated. Although it is highly unlikely
that a future randomized control trial will identify the
optimal approach, individual centers can be better
stewards of antimicrobials by closely monitoring their
individual infection rates and the associated microbiol-
ogy. Besides specific antimicrobial agents, efforts to
ensure optimization of dosing strategies (e.g., admin-
istration within 1 hour before incision, redosing for pro-
longed operations, etc.) are a critical aspect of surgical
site infection (SSI) prevention. In addition, active ef-
forts to decrease the duration of prophylaxis should
be promoted. Clinical teams providing postoperative
care should carefully consider whether there is any
real benefit to extending the duration of perioperative
antimicrobials, particularly vancomycin.5 The use of au-
tomatic stop orders may also be helpful.
In addition to systemic antimicrobials, there may
be a larger role for chlorhexidine to prevent device
infection, particularly in terms of driveline infections.
As noted above, 11 centers reported routine use of
chlorhexidine. Recent studies demonstrate the bene-
fits of chlorhexidine bathing among patients with cen-
tral venous catheters, including those in the ICU set-
ting as well as the long-term acute care hospital.7,8 A
modified strategy may have efficacy in regards to SSI
prevention among LVAD recipients, especially in re-
gard to driveline infection. Future research should help
determine which agents provide the best outcomes
for patients while providing the fewest doses of broad-
spectrum therapy. Such studies should also consider
potential decolonization strategies including those us-
ing chlorhexidine.
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